HUB Organoids Announces New Corporate Strategy and Completes Transition from Foundation to Private Company

July 18, 2023

HUB Organoids Announces New Corporate Strategy and Completes Transition from Foundation to Private Company

[Utrecht, July 18 2023] — HUB Organoids (HUB), the global leader in the field of patient-derived organoids, is excited to announce a...

read more

HUB Organoids extends partnership with Molecular Devices to advance automated intestinal organoid screening technology

March 4, 2023

HUB Organoids extends partnership with Molecular Devices to advance automated intestinal organoid screening technology

SAN JOSE, Calif., and UTRECHT, Netherlands, Feb. 13, 2023 – Molecular Devices, LLC., a leading provider of high-performance life science solutions, and...

read more

HUB Organoids take their first parabolic flight!

March 4, 2023

HUB Organoids take their first parabolic flight!

read more

FDA Modernization Act 2.0:  We welcome the dawn of an organoid era

March 4, 2023

FDA Modernization Act 2.0: We welcome the dawn of an organoid era

read more

Imagine Reducing the Time to Identify a Drug

April 28, 2022

Imagine Reducing the Time to Identify a Drug

Patients with mutated KRAS (Kirsten rat sarcoma virus) gene account for around 30-50% of the population with colorectal cancer (CRC) and do...

read more

Exclusive interview with Dr Carla Verissimo

November 10, 2021

Exclusive interview with Dr Carla Verissimo

Our Carla Verissimo, Head of Oncology II speaks about the current challenges of oncology drug development in this exclusive interview of the...

read more

New PERSIST-SEQ program launched

September 2, 2021

New PERSIST-SEQ program launched

2 September 2021, Utrecht (The Netherlands) - Hubrecht Organoid Technology (HUB) joins a new international consortium of academic and industrial leaders in...

read more

Link revealed between HBV infection and liver cancer

August 31, 2021

Link revealed between HBV infection and liver cancer

HUB Organoids derived from patients with chronic hepatitis B show the first molecular signs of liver cancer. The molecular events that drive...

read more

New service partnership

August 18, 2021

New service partnership

VANCOUVER, British Columbia - STEMCELL Technologies and Hubrecht Organoid Technology (HUB) have announced that they have signed an agreement for the use...

read more

CF models for drug development

August 12, 2021

CF models for drug development

HUB Organoids™ supports the on-going clinical evaluation of ELX-02 as a therapeutic agent for cystic fibrosis (CF). HUB Organoids™ advance treatment for...

read more

X

Have any questions?

contact us